CEFEPIME HYDROCHLORIDE Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Cefepime Hydrochloride, and what generic alternatives are available?
Cefepime Hydrochloride is a drug marketed by Acs Dobfar, Astral, Fosun Pharma, Hospira Inc, Qilu, Sagent Pharms Inc, and Samson Medcl. and is included in eight NDAs.
The generic ingredient in CEFEPIME HYDROCHLORIDE is cefepime hydrochloride. There are twenty drug master file entries for this compound. Ten suppliers are listed for this compound. Additional details are available on the cefepime hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Cefepime Hydrochloride
A generic version of CEFEPIME HYDROCHLORIDE was approved as cefepime hydrochloride by ACS DOBFAR on March 20th, 2008.
Summary for CEFEPIME HYDROCHLORIDE
US Patents: | 0 |
Applicants: | 7 |
NDAs: | 8 |
Finished Product Suppliers / Packagers: | 7 |
Raw Ingredient (Bulk) Api Vendors: | 114 |
Clinical Trials: | 60 |
Patent Applications: | 484 |
Formulation / Manufacturing: | see details |
DailyMed Link: | CEFEPIME HYDROCHLORIDE at DailyMed |
Recent Clinical Trials for CEFEPIME HYDROCHLORIDE
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Meiji Seika Pharma Co., Ltd. | Phase 3 |
Allecra | Phase 2 |
Linical Co., Ltd. | Phase 2 |
Pharmacology for CEFEPIME HYDROCHLORIDE
Drug Class | Cephalosporin Antibacterial |